Found 23 results
[ Author(Asc)] Keyword Title Type Year
Filters: First Letter Of Last Name is R  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
G. J. S. Rustin, Use of CA-125 to assess response to new agents in ovarian cancer trials, J Clin Oncol, vol. 21, p. 187s-193s, 2003.
G. J. S. Rustin, Nelstrop, A., Bentzen, S. M., Piccart, M. J., and Bertelsen, K., Use of tumour markers in monitoring the course of ovarian cancer., Ann Oncol, vol. 10 Suppl 1, pp. 21-7, 1999.
G. J. S. Rustin, Timmers, P., Nelstrop, A., Shreeves, G., Bentzen, S. M., Baron, B., Piccart, M. J., Bertelsen, K., Stuart, G. C. E., Cassidy, J., and Eisenhauer, E., Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide., J Clin Oncol, vol. 24, no. 1, pp. 45-51, 2006.
G. J. S. Rustin, van der Burg, M. E. L., and Berek, J. S., Advanced ovarian cancer. Tumour markers., Ann Oncol, vol. 4 Suppl 4, pp. 71-7, 1993.
G. J. S. Rustin, Quinn, M., Thigpen, T., du Bois, A., Pujade-Lauraine, E., Jakobsen, A., Eisenhauer, E., Sagae, S., Greven, K., Vergote, I. B., Cervantes, A., and Vermorken, J. B., Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)., J Natl Cancer Inst, vol. 96, no. 6, pp. 487-8, 2004.
G. J. S. Rustin, Use of CA-125 to assess response to new agents in ovarian cancer trials., J Clin Oncol, vol. 21, no. 10 Suppl, p. 187s-193s, 2003.
G. J. S. Rustin, Vergote, I. B., Eisenhauer, E., Pujade-Lauraine, E., Quinn, M., Thigpen, T., du Bois, A., Kristensen, G. B., Jakobsen, A., Sagae, S., Greven, K., Parmar, M. K. B., Friedlander, M. Leonard, Cervantes, A., Vermorken, J. B., and Intergroup, G. Cancer, Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG), Int J Gynecol Cancer, vol. 21, pp. 419-23, 2011.
M. Rotman, Pajak, T. F., Choi, K., Clery, M., Marcial, V., Grigsby, P. W., Cooper, J., and John, M., Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20, JAMA, vol. 274, pp. 387-93, 1995.
M. L. Rothenberg, Liu, P. Y., Braly, P. S., Wilczynski, S. P., Hannigan, E. V., Wadler, S., Stuart, G. C. E., Jiang, C., Markman, M., and Alberts, D. S., Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial., J Clin Oncol, vol. 21, no. 7, pp. 1313-9, 2003.
P. G. Rose, Nerenstone, S., Brady, M. F., Clarke-Pearson, D. L., Olt, G., Rubin, S. C., Moore, D. H., Small, J. M., and Group, G. Oncology, Secondary surgical cytoreduction for advanced ovarian carcinoma, N Engl J Med, vol. 351, pp. 2489-97, 2004.
F. T. Roncolato, O'Connell, R., Joly, F., Lanceley, A., Hilpert, F., Okamoto, A., Aotani, E., Pignata, S., Donnellan, P. P., Oza, A. M., Åvall-Lundqvist, E., Berek, J. S., Sjoquist, K. Marie, Gillies, K., Butow, P., Stockler, M. R., King, M. Trudy, and Friedlander, M. Leonard, Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS ≥ 3) recurrent ovarian cancer (ROC) receiving ≥ 3 lines of chemotherapy: The GCIG Symptom Benefit Study (SBS).. 2015.
N. Simon Reed, Mangioni, C., Malmström, H., Scarfone, G., Poveda, A. M., Pecorelli, S., Tateo, S., Franchi, M., Jobsen, J. J., Coens, C., Teodorovic, I., Vergote, I. B., and Vermorken, J. B., Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)., Eur J Cancer, vol. 44, no. 6, pp. 808-18, 2008.
N. Simon Reed, Gomez-Garcia, E., Gallardo-Rincon, D., Barrette, B. A., Baumann, K. H., Friedlander, M. Leonard, Kichenadasse, G., Kim, J. - W., Lorusso, D., Mirza, M. Raza, and Ray-Coquard, I., Gynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S35-41, 2014.
N. Simon Reed, Pautier, P., Åvall-Lundqvist, E., Choi, C. - H., du Bois, A., Friedlander, M. Leonard, Fyles, A., Kichenadasse, G., Provencher, D. M., and Ray-Coquard, I., Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian small cell cancers., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S30-4, 2014.
N. Simon Reed, Poole, C. J., Coleman, R. L., Parkin, D., Graham, J. D., Kaye, S. B., Ostrowski, J., Duncan, I., Paul, J., Hay, A., and Group, S. Gynaecolog, A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: A study by the Scottish Gynaecological Cancer Trials Group (SGCTG), Eur J Cancer, vol. 42, pp. 179-85, 2006.
I. Ray-Coquard, Weber, B., Lotz, J. P., Tournigand, C., Provencal, J., Mayeur, D., Treilleux, I., Paraiso, D., Duvillard, P., Pujade-Lauraine, E., and Group, G. I. N. E. C. O., Management of rare ovarian cancers: the experience of the French website "Observatory for rare malignant tumours of the ovaries" by the GINECO group: interim analysis of the first 100 patients, Gynecol Oncol, vol. 119, pp. 53-9, 2010.
I. Ray-Coquard, Weber, B., Cretin, J., Haddad-Guichard, Z., Levy, E., Hardy-Bessard, A. C., Gouttebel, M. C., Geay, J. - F., Aleba, A., Orfeuvre, H., Agostini, C., Provencal, J., Ferrero, J. M., Fric, D., Dohollou, N., Paraiso, D., Salvat, J., Pujade-Lauraine, E., and Group, G. I. N. E. C. O., Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group, Br J Cancer, vol. 100, pp. 601-7, 2009.
I. Ray-Coquard, Brown, J., Harter, P., Provencher, D. M., Fong, P. C., Maenpaa, J. U., Ledermann, J. A., Emons, G., Rigaud, D. Berton, Glasspool, R. M., Mezzanzanica, D., and Colombo, N., Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S42-7, 2014.
I. Ray-Coquard, Paraiso, D., Guastalla, J. P., Leduc, B., Guichard, F., Martin, C., Chauvenet, L., Haddad-Guichard, Z., Lepille, D., Orfeuvre, H., Gautier, H., Castera, D., and Pujade-Lauraine, E., Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group, Br J Cancer, vol. 97, pp. 1200-5, 2007.
M. Randall, Filiaci, V. L., Muss, H., Spirtos, N. M., Mannel, R., Fowler, J. M., Thigpen, J. T., Benda, J. A., and Study, G. Oncology G., Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study, J Clin Oncol, vol. 24, pp. 36-44, 2006.
L. M. Randall, Sill, M. W., Burger, R. A., Monk, B. J., Buening, B., and Sorosky, J. I., Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial, Gynecol Oncol, vol. 124, pp. 563-8, 2012.
F. A. Raja, Griffin, C. L., Qian, W., Hirte, H., Parmar, M. K. B., Swart, A. Marie, and Ledermann, J. A., Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer., Br J Cancer, vol. 105, no. 7, pp. 884-9, 2011.
F. A. Raja, Counsell, N., Colombo, N., Pfisterer, J., du Bois, A., Parmar, M. K. B., Vergote, I. B., Gonzalez-Martin, A., Alberts, D. S., Plante, M., Torri, V., and Ledermann, J. A., Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data., Ann Oncol, vol. 24, no. 12, pp. 3028-34, 2013.